Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN)

Dyne Therapeutics, Inc. (NASDAQ:DYN) is among the 14 best booming stocks to buy right now, with returns of over 23% in the last three months. Wall Street analysts have a consensus Strong Buy rating on the stock and project a further 120% upside as of the close on January 12.

Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN)

Recent analyst updates include Evercore ISI’s Gavin Clark-Gartner on December 17, trimming the firm’s price target on the stock to $36 from $38, while maintaining an earlier Outperform rating.

According to TipRanks, the firm praised the company for its functionality and meeting expectations on metrics such as safety and efficacy. Despite the cut, the revised price target represents an upside potential of over 100% from Monday’s close.

Earlier on December 10, Oppenheimer upgraded the stock’s rating to Outperform and lifted its price target to $40 from $11 on December 10, citing the anticipated Phase 3 trial readout for competitor Avidity’s RNA therapy, del-desiran in myotonic dystrophy type 1, in the second half of 2026.

According to Oppenheimer, another significant upside catalyst for Dyne Therapeutics, Inc. (NASDAQ:DYN) this year could be the success of its zeleciment basivarsen therapeutic to treat patients living with myotonic dystrophy type 1 (DM1). Moreover, the likelihood of the FDA reviewing the company’s candidate for Duchenne muscular dystrophy (DMD) could also help the stock rally.

Dyne Therapeutics, Inc. (NASDAQ:DYN) is a healthcare company focused on developing treatments for patients of genetically driven neuromuscular diseases.

While we acknowledge the risk and potential of DYN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DYN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.